An Oversupply Of COVID Antibody Treatments? Multiple Monoclonal Products Raise Potential For Errors

As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.

Molecular model of antibody taking part in immune defence. Molecule of immunoglobulin, 3D illustration
The US government is ready to begin allocation of Regeneron's casirivimab-imdevimab monoclonal antibody combination, which just received an EUA for use as a COVID-19 treatment. • Source: Shutterstock

US government officials are keeping a close watch for a spike in medication errors now that multiple monoclonal antibodies are available for treatment of the coronavirus.

Regeneron Pharmaceuticals, Inc. became the second sponsor to receive an emergency use authorization for a monoclonal antibody on 21...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet